RxDoctor Payments Data

Susan Heifetz, MD

Internal Medicine · Vista, CANPI 1831289297

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 86 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$239
  • AstraZeneca$231
  • Novartis$163
  • Novo Nordisk$147
  • GSK$133
  • Astellas Pharma US Inc$101
  • plus $379 from 12 others

What the payments were for

  • Food & beverage$1,35998%
  • Gifts$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,393 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$65,309
Medicare patients
200
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$175,058
EliquisApixaban57$65,532
MyrbetriqMirabegron31$32,854
JardianceEmpagliflozin24$32,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,582
JanuviaSitagliptin Phosphate28$26,135
MounjaroTirzepatide21$22,324
XareltoRivaroxaban21$21,704
FarxigaDapagliflozin Propanediol14$18,676
Breo ElliptaFluticasone/Vilanterol28$13,130
LinzessLinaclotide14$11,723
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$8,538
Repatha SyringeEvolocumab14$8,454
NucyntaTapentadol Hcl12$8,439
Tresiba Flextouch U-200Insulin Degludec14$8,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$175,058172 claims
PfizerEliquis$68$65,53257 claims
GSKTrelegy Ellipta, Breo Ellipta$133$45,71264 claims
Astellas Pharma US IncMyrbetriq$101$32,85431 claims
Boehringer IngelheimJardiance$34$32,76324 claims
MerckJanuvia$13$26,13528 claims
Lilly USA, LLCMounjaro$76$22,32421 claims
Johnson & JohnsonXarelto$14$21,70421 claims
AstraZenecaFarxiga$231$18,67614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →